TY - JOUR AU - Mamontova, Tetiana PY - 2022/05/31 Y2 - 2024/03/28 TI - DIAGNOSIS AND PROGNOSIS SIGNIFICANCE OF IMMUNOLOGICAL MARKERS IN MIDDLE AND SEVERE COVID-19: META-ANALYSIS JF - Immunology and Allergology: Science and Practice JA - Immun. and Allerg.: Sci. and Pract. VL - 0 IS - 4 SE - Articles DO - 10.37321/immunology.2021.4-04 UR - https://immunology.org.ua/index.php/journal/article/view/60 SP - 39-45 AB - Background. COVID-19 continues to be an urgent medical and social problem of unprecedented proportions for the health care system in Ukraine. Currently, there is an increase in the prevalence of morbidity and mortality from COVID-19. Therefore, it is necessary to determine immunological markers of stratification of patients at high risk of complications and mortality.The aim: to conduct a meta-analysis of immunological markers to identify predictors of mild or severe COVID-19.Materials and methods. Meta-analysis of 16 electronic publications in PubMed, Google Scholar, medRXiV by keywords “COVID-19” or “2019-nCoV” or “SARSCoV- 2”, “immune markers” in the period from 2019 to 2022. The meta-analysis included publications on a clinical examination of 1731 patients with COVID-19, divided into 2 groups: the first -with mild (n = 1055) and the second –with severe (n = 679) Sars-CoV-2 infection. Statistical data processing by meta-analysis, non-parametric Student’s t-test and criterion χ2.Research results and their discussion. There are was significantly higher mean age and proportion of males in patients with severe COVID-19 than in patients with mild COVID-19 (p = 0.0001; p = 0.009, respectively). Significantly lower absolute values of CD3+ (-1.02; CI [-1.443, -0.59]; p = 0.004), CD3+ CD4+(-1.34; CI [-2.117, -0.569]; p = 0.0007), CD3+CD8+(-1.49; CI [-2.244, -0.728]; p = 0.0001) T-lymphocytes, CD16+CD56+ natural killers (-1.02; CI [-1.904, -0.138]); p = 0,02), CD19+ B-lymphocytes (-1.12; CI [-2.077, -0.156]; p = 0.023), complement component C1q (-1.94; CI [-3.693, -0.182]; p = 0.03) and C3 (-2.93; CI [-5.422, -0.444]; p = 0.02), as well as significantly higher indicators of IL-6 (1.54; CI [0.57, 2.509]; p = 0.004), IL-8 (0.93; CI [0.116, 1.747]; p = 0.001) and IL-10 (2.55; CI [1.135, 3.97]; p = 0.004) in patients with severe COVID-19 than in patients with mild COVID-19.Conclusions: Determination of the level of immunological markers, as CD3+, CD3+CD4+, CD3+CD8+ T-lymphocytes, CD16+CD56+ natural killers, CD19+ B-lymphocytes, C1q and C3 components of complement and IL-6, IL-8 and IL-10 can be used as early predictors of severe COVID-19. ER -